| Project/Area Number |
23650599
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
KONDO Shigetada 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 特任助教 (40304513)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ノンゴーディングRNA / 悪性腫瘍 / ノンコーディングＲＮＡ / VEGF / 腫瘍血管新生 / 機能性RNA / ノンコーティングRNA / 血管新阻害剤 |
|---|
| Research Abstract |
I have investigated the direct effects of antiangiogenic agents on tumor cells, and revealed that treatment of cancer cells with vascular endothelial growth factor (VEGF)-targeting agents, including avastin and VEGF receptor multi kinase inhibitor, induced novel protein-non-coding RNAs. Overexpression of these non-coding RNAs made tumor cells resistant to anticancer drug- and hypoxia-induced apoptosis. In this research project, I developed two efficient siRNAs targeting novel tumor-promoting non-conding RNAs (ncRNAs). I evaluated efficacy ofthose siRNA on tumor cells and xenograft tumors. Knockdown of ncRNAs increased apoptosis of tumor cells by cytotoxic anticancer drugs (5-FU, cisplatin, etoposide). Furthermore, knockdown of ncRNAs in xenograft tumors enhanced antitumor effects of those cytotoxic anticancer agnets.
|
